RxDoctor Payments Data

Shirley Kuan

Adult Health · Bridgeport, CTNPI 1255938940

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 260 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 30.8% of the total. Reporting peaked in 2023 at $3,418 and has fallen 99.5% since, to $19 in 2025. Among adult health clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,625in general payments, 2019–2025

Across 260 payments — averaging $21.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$825
  • Novo Nordisk$508
  • Pfizer$342
  • Viiv Healthcare Company$329
  • Gilead$240
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$5,625100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,625 in reported general payments places this provider in the 90th percentile of 418 adult health providers in Connecticut.

See all adult health providers in Connecticut

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol32$33,476
JardianceEmpagliflozin22$21,890
OzempicSemaglutide13$12,574
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$11,437
TradjentaLinagliptin13$10,542
SymbicortBudesonide/Formoterol Fumarate20$6,470
Albuterol Sulfate HfaAlbuterol Sulfate75$1,712
Ventolin HfaAlbuterol Sulfate28$1,605
Comfort Ez Pen NeedlePen Needle, Diabetic11$1,254
Alcohol Prep PadsAlcohol Antiseptic Pads17$788
Atorvastatin Calcium90$742
Famotidine38$648
Fluticasone Propionate35$517
Rosuvastatin Calcium35$480
Metoprolol Succinate33$461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$825$51,38471 claims
Boehringer IngelheimJardiance, Tradjenta$169$32,43235 claims
Novo NordiskOzempic$508$12,57413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 418 adult health providers in Connecticut.

Other adult health in Bridgeport

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →